A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease
Latest Information Update: 11 Jul 2025
At a glance
- Drugs Empagliflozin (Primary) ; Vicadrostat (Primary)
- Indications Heart failure; Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms EASi-KIDNEY
- Sponsors Boehringer Ingelheim
Most Recent Events
- 25 Feb 2025 Planned End Date changed from 31 Jan 2029 to 30 Aug 2028.
- 25 Feb 2025 Planned primary completion date changed from 31 Jan 2029 to 30 Aug 2028.
- 10 Feb 2025 Planned End Date changed from 30 Aug 2028 to 31 Jan 2029.